Mylan Expands its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to All Lots Within Expiry Due to ...

The 29 lots of single and 51 lots of combination Valsartan medicines distributed under the Actavis label in the U.S. are being recalled due to the detection of trace amounts of an unexpected ...

Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/320 mg/25 mg, 90-count bottles, lot. No. 22x045 expiration 2/2019. Patients with questions can call Teva at 888-838-2872, push option ...

Find out how to take Amlodipine, Valsartan and Hydrochlorothiazide (drug) and its dose. Describes the best time to take the drug and precautions if any that should be followed.

Issue: Several drugs containing the ingredient valsartan are being recalled by their manufacturers. An impurity, N-nitrosodimethylamine (NDMA), was found in the valsartan used in these products.

The United States Food and Drug Administration said that Prinston Pharmaceutical Inc. dba Solco Healthcare LLC. is recalling all lots of Valsartan Tablets, 40 mg, 80mg, 160mg, and 320mg; and ...

The recall involves 104 lots of three medicines: valsartan tablets; combination tablets with the drugs valsartan and amlodipine; and combination tablets with valsartan and hydrochlorothiazide.

Also: 51 lots of Valsartan tablets, USP (including 40 mg, 80 mg, 160 mg and 320 mg strengths), and 27 lots of Valsartan and Hydrochlorothiazide tablets, USP (80mg/12.5mg, 160mg/12.5mg, 160mg/25mg ...

A voluntary recall of valsartan, a drug used to treat high blood pressure and heart failure, has expanded for increased risk of contamination with a cancer-causing agent.

At study initiation patients assigned to the 2-component arms received lower doses of their treatment combination while patients assigned to the Exforge HCT® arm received 160/12.5 mg valsartan ...

Results of a study exploring the effects of antihypertensive therapy on CRP levels show that valsartan reduced CRP independent of the degree of BP reduction in patients with stage 2 hypertension ...

Aurobindo Pharma Ltd has informed BSE regarding a Press Release dated March 22, 2013, titled "Aurobindo Pharma receives USFDA final approval for Valsartan and Hydrochlorothiazide Tablets".